Literature DB >> 1972142

Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester.

U Salge1, P Kilian, K Neumann, H P Elsässer, K Havemann, H H Heidtmann.   

Abstract

Three cell lines of squamous-cell carcinoma and 3 of large-cell carcinoma origin were investigated for the expression of differentiation markers and functional parameters (proliferation, morphology, cornified envelope formation, involucrin staining, transglutaminase activity, adhesiveness and migration) under normal cell culture conditions and after treatment with the tumor promoter phorbol-12-myristate-13-acetate (PMA). Although all original tumors had been described as poorly differentiated by histological grading, we found significant heterogeneity in the expression of differentiation markers in cell culture. A systematic grading of the cell lines became possible only after PMA stimulation. PMA generally increased expression of differentiation markers in cell lines of comparably low grades of differentiation, as indicated by dose-dependent inhibition of proliferation and cloning efficiency, induction of squamous markers, and decreased adhesiveness and cell motility. In contrast, cell lines of apparently higher differentiation by these criteria showed little response to PMA. The results presented show that the assessment of differentiation capacity by comparison of differentiation markers under normal cell culture and PMA-stimulated conditions in established NSCLC cell lines allows for a refined cell culture grading, which might advance the classification and characterization of such cell lines which, otherwise, appear to be very heterogeneous. It may also help to correlate cellular functions with various states of differentiation in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972142     DOI: 10.1002/ijc.2910450626

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.

Authors:  Z T Han; X X Zhu; R Y Yang; J Z Sun; G F Tian; X J Liu; G S Cao; H L Newmark; A H Conney; R L Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.

Authors:  H H Heidtmann; U Salge; M Abrahamson; M Bencina; L Kastelic; N Kopitar-Jerala; V Turk; T T Lah
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

Review 3.  Anti-cancer activities of Schedule E1 drugs used in ayurvedic formulations.

Authors:  E N T Vikram; R Ilavarasan; R Kamaraj
Journal:  J Ayurveda Integr Med       Date:  2022-05-31

4.  Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.

Authors:  P Correale; A Procopio; L Celio; M Caraglia; G Genua; V Coppola; S Pepe; N Normanno; I Vecchio; G Palmieri
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta.

Authors:  H H Heidtmann; K Havemann; R Schwartz-Albiez
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

6.  12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells.

Authors:  G J Rabiasz; S P Langdon; L Anderson; A A Ritchie; W R Miller; J F Smyth
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.